Dulaglutide (Trulicity), another once-weekly GLP-1 agonist, reports injection site reaction rates of approximately 0.7% in its FDA label
(2018) 42:e13846
Syngenes FY26 was, by its own standards, a disappointing year
In addition, an illustration of variability in a dosing interval was included for the dose-normalised steady-state concentrations from the target semaglutide doses 0.5 and 1.0 mg (Fig
Many of the large direct-to-consumer companies selling them, like Ro Health and Hims, are household names, publicly traded on the New York Stock Exchange and servicing thousands of patient-consumers, providing prescriptions to treat conditions like depression, smoking cessation, and hair loss
Of course, you could always use Fella for weight loss and hims for everything else